오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amlodipine besilate, quantity: 6.93 mg (equivalent: amlodipine, qty 5 mg) - tablet - excipient ingredients: sodium starch glycollate type a; silicon dioxide; calcium phosphate; magnesium stearate; microcrystalline cellulose - hypertension pharmacor amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of pharmacor amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina pharmacor amlodipine is indicated for the first line treatment of chronic stable angina. pharmacor amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet - excipient ingredients: calcium phosphate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; silicon dioxide - hypertension pharmacor amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of pharmacor amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina pharmacor amlodipine is indicated for the first line treatment of chronic stable angina. pharmacor amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: pectin; mannitol; isopropyl alcohol; hyprolose; purified talc; lactose monohydrate; purified water; triacetin; titanium dioxide; magnesium stearate; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: purified water; lactose monohydrate; titanium dioxide; isopropyl alcohol; pectin; magnesium stearate; triacetin; hyprolose; purified talc; mannitol; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; triacetin; isopropyl alcohol; pectin; titanium dioxide; magnesium stearate; hyprolose; mannitol; purified talc; purified water; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: purified talc; hyprolose; magnesium stearate; lactose monohydrate; titanium dioxide; mannitol; isopropyl alcohol; pectin; purified water; triacetin; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: stearic acid; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; stearic acid; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, gliclazide mr 30 mg tablets, taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - amlodipine besilate, quantity: 6.9335 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate - hypertension: amlodipine gh tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoreceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlodipine gh tablets are indicated for the first line treatment of chronic stable angina. amlodipine gh tablets may be used alone, as monotherapy or in combination with other antianginal drugs.

미국 - 영어 - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 100 mg - carbamazepine is indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general). carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marrow depression, hypersensitivity to the drug, or known sensitivity to any of the tricyclic compounds, such as amitriptyline, desipramine, imipramine, protriptyline, nortriptyline, etc. likewise, on theoretical grounds its use with monoamine oxidase (mao) inhibitors is not recommended. before administration of carbamazepine, mao inhibitors should be discontinued for a minimum of 14 days, or longer if the clinical situation permits. coadministration of carbamazepine and nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect. coadministration of carbamazepine with nefazodone is contraindicated. no evidence of abuse potential has been associated with carbamazepine, nor is there evidence of psychological or physical dependence in humans.